CJC-1295 won't be found on pharmacy shelves in Coats or virtually any local market — it's a research compound available through a dedicated online market. This matters because CJC-1295 quality varies dramatically across the market — from analytically confirmed high-purity product to mislabeled or underdosed compounds — and the vendor is the entire quality system. What genuinely separates top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety documentation. This guide takes Coats researchers through that evaluation process and explains how to verify CJC-1295 vendor quality step by step.
CJC-1295 Mechanisms Explained
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Coats comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade CJC-1295
Evaluating CJC-1295 vendors begins with the COA: locate the batch-specific certificate before placing an order, not after. When reviewing a CJC-1295 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are at acceptable levels for the intended application. For Coats researchers evaluating vendors with limited track records: a modest first purchase to test the product before scaling up your order is standard practice in the community. For Coats researchers making a first CJC-1295 purchase: apply these quality criteria before ordering, begin with a small order, and verify batch traceability on arrival before use.
Order CJC-1295 — ships to Coats
COA-verified · International tracking · Research grade
CJC-1295 operates outside approved pharmaceutical regulation — researchers should understand that the safety data available for CJC-1295 is based on academic studies rather than pharmaceutical approval data. Temperature excursions — even short periods above −20°C — can compromise product integrity without visible changes; always use only material shipped with appropriate cold protection. The primary quality-related safety risk in CJC-1295 research is bacterial endotoxin from low-quality material — a verified endotoxin panel in the batch COA is the key safeguard. For any individual considering CJC-1295 outside a formal research context: speak with a healthcare professional — this compound is not a licensed human medication and its risk profile is not equivalent to approved medications.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
